Overview

• 10X Genomics Q2 revenue of $172.9 mln beats analyst expectations, per LSEG data

• Net income for Q2 was $34.5 mln, reversing a loss from last year

• Co acquires Scale Biosciences to strengthen single cell analysis capabilities

Outlook

• Company expects Q3 2025 revenue between $140 mln and $144 mln

• 10X Genomics notes revenue acceleration due to anticipated tariff changes

• Company highlights uncertainty in funding environment impacting outlook

• 10X Genomics emphasizes long-term opportunity amid market challenges

Result Drivers

• REVENUE DECLINE - 5% decrease in revenue excluding litigation settlement, driven by lower instrument sales

• GROSS MARGIN INCREASE - Higher license and royalty revenue improved gross margin to 72%

• CHINA PURCHASES - $4 mln in revenue from accelerated purchases by Chinese customers due to tariff concerns

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for 10X Genomics Inc is $14.00, about 9.6% above its August 6 closing price of $12.66

Press Release: ID:nPnWjV2ga

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)